Fingerprint
Dive into the research topics of 'ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis
Francis J Gilchrist*, Stephanie Bui, Silvia Gartner, Susanna A McColley, Harm Tiddens, Gary Ruiz, Florian Stehling, Muhsen Alani, Oksana Gurtovaya, Mark Bresnik, Timothy R Watkins, Biliana Frankovic, Marianne Skov, ALPINE2 study investigators
*Corresponding author for this work
1
Citation
(Scopus)